Repository logo
 
Publication

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13

dc.contributor.authorKissling, E.
dc.contributor.authorValenciano, M.
dc.contributor.authorBuchholz, U.
dc.contributor.authorLarrauri, A.
dc.contributor.authorCohen, J.M.
dc.contributor.authorNunes, Baltazar
dc.contributor.authorRogalska, J.
dc.contributor.authorPitigoi, D.
dc.contributor.authorParadowska-Stankiewicz, I.
dc.contributor.authorReuss, J.
dc.contributor.authorJiménez-Jorge, S.
dc.contributor.authorDaviaud, I.
dc.contributor.authorGuiomar, R.
dc.contributor.authorO'Donnell, J.
dc.contributor.authorNecula, G.
dc.contributor.authorGłuchowska, M.
dc.contributor.authorMoren, A.
dc.date.accessioned2015-01-23T14:56:03Z
dc.date.available2015-01-23T14:56:03Z
dc.date.issued2014-02-13
dc.description.abstractIn the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a multicentre case–control study (MCCS) in seven European Union (EU) Member States to measure 2012/13 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory confirmed as influenza. The season was characterised by substantial co-circulation of influenza B, A(H1N1)pdm09 and A(H3N2) viruses. Practitioners systematically selected ILI patients to swab ≤7 days of symptom onset. We compared influenza-positive by type/subtype to influenza-negative patients among those who met the EU ILI case definition. We conducted a complete case analysis using logistic regression with study as fixed effect and calculated adjusted vaccine effectiveness (AVE), controlling for potential confounders (age, sex, symptom onset week and presence of chronic conditions). We calculated AVE by type/subtype. Study sites sent 7,954 ILI/acute respiratory infection records for analysis. After applying exclusion criteria, we included 4,627 ILI patients in the analysis of VE against influenza B (1,937 cases), 3,516 for A(H1N1)pdm09 (1,068 cases) and 3,340 for influenza A(H3N2) (730 cases). AVE was 49.3% (95% confidence interval (CI): 32.4 to 62.0) against influenza B, 50.4% (95% CI: 28.4 to 65.6) against A(H1N1)pdm09 and 42.2% (95% CI: 14.9 to 60.7) against A(H3N2). Our results suggest an overall low to moderate AVE against influenza B, A(H1N1)pdm09 and A(H3N2), between 42 and 50%. In this season with many co-circulating viruses, the high sample size enabled stratified AVE by type/subtype. The low estimates indicate seasonal influenza vaccines should be improved to achieve acceptable protection levels.por
dc.identifier.citationEuro Surveill. 2014 Feb 13;19(6). pii: 20701. doi:10.2807/1560-7917.ES2014.19.6.20701por
dc.identifier.doi10.2807/1560-7917.ES2014.19.6.20701
dc.identifier.issn1560-7917
dc.identifier.urihttp://hdl.handle.net/10400.18/2688
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherECDC-European Centre for Disease Prevention and Controlpor
dc.relationI-MOVEpor
dc.relation.publisherversionhttp://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20701por
dc.subjectInfluenzapor
dc.subjectVaccinepor
dc.subjectEffectivenesspor
dc.subjectCuidados de Saúdepor
dc.titleInfluenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13por
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceStockholm, Swedenpor
oaire.citation.endPagepii: 20701por
oaire.citation.startPagepii: 20701por
oaire.citation.titleEurosurveillancepor
oaire.citation.volume19(6)por
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
art20701.pdf
Size:
496.71 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: